Sylvester Cancer Center: A Leader in National Cancer Policy
Table of Contents
- 1. Sylvester Cancer Center: A Leader in National Cancer Policy
- 2. Seven Ways Sylvester Has Influenced Cancer Policy
- 3. Minimal Residual Disease Advice to the FDA
- 4. Sylvester Researcher Plays Key role in Potential Game-Changer for Multiple Myeloma Treatment
- 5. Oncology Nursing Society president
- 6. Sylvester nurse makes History as Oncology Nursing society President
- 7. National Cancer survivorship Standards
- 8. Pancreatic Cancer Action Network
- 9. Renowned Oncologist Dr. Peter Hosein Joins Pancreatic Cancer Action Network’s Scientific Advisory Board
- 10. University of Miami Radiation Oncologist Invited to White House roundtable
- 11. University of Miami Physicians Contribute to National Cancer Initiatives
- 12. National Minority Quality Forum Cancer stage Shifting Initiative
- 13. Sylvester Researchers Focus on Ovarian Cancer and African Ancestry
- 14. Breaking Barriers: Sylvester Researchers Spearhead Ovarian Cancer Study focused on African Descent Women
- 15. Team of Experts at the Forefront
Table of Contents
- 1. Sylvester Cancer Center: A Leader in National Cancer Policy
- 2. Seven Ways Sylvester Has Influenced Cancer Policy
- 3. Minimal Residual Disease Advice to the FDA
- 4. Sylvester Researcher Plays Key role in Potential Game-Changer for Multiple Myeloma Treatment
- 5. Oncology Nursing Society president
- 6. Sylvester nurse makes History as Oncology Nursing society President
- 7. National Cancer survivorship Standards
- 8. Pancreatic Cancer Action Network
- 9. Renowned Oncologist Dr. Peter Hosein Joins Pancreatic Cancer Action Network’s Scientific Advisory Board
- 10. University of Miami Radiation Oncologist Invited to White House roundtable
- 11. University of Miami Physicians Contribute to National Cancer Initiatives
- 12. National Minority Quality Forum Cancer stage Shifting Initiative
- 13. Sylvester Researchers Focus on Ovarian Cancer and African Ancestry
- 14. Breaking Barriers: Sylvester Researchers Spearhead Ovarian Cancer Study focused on African Descent Women
- 15. Team of Experts at the Forefront
Sylvester Thorough Cancer Center, a renowned institution affiliated with the University of Miami Miller School of Medicine, has been instrumental in shaping national cancer-related policies and securing crucial funding. through the dedicated efforts of its physician-scientists, Sylvester has consistently championed initiatives aimed at elevating patient care, optimizing treatment outcomes, and ultimately saving lives.
Sylvester plays a pivotal role in advancing cancer research by actively collaborating with various federal programs and agencies under the Department of Health and Human Services (HHS). These include the National Cancer Institute (NCI), the National Institutes of Health (NIH), and the U.S. Food and Drug Administration (FDA). Sylvester’s researchers contribute as subject-matter experts on non-profit boards and actively participate in significant initiatives like the White House Cancer Moonshot. As an NCI-designated center, Sylvester uses its expertise and advocacy to drive meaningful changes in cancer programs and patient care on a national scale.
Seven Ways Sylvester Has Influenced Cancer Policy
Sylvester’s impact on national cancer policy is multifaceted.Here are seven key ways the center has made a difference:
Minimal Residual Disease Advice to the FDA
Sylvester researchers played a crucial role in advocating for the use of minimal residual disease (MRD) as an endpoint in clinical trials for certain blood cancers. This recommendation to the FDA has the potential to significantly impact the advancement of new and more effective cancer therapies.
Sylvester Researcher Plays Key role in Potential Game-Changer for Multiple Myeloma Treatment
In April, an advisory committee to the FDA voted in favor of a new approach to evaluating treatments for multiple myeloma. This decision came after a presentation by Dr. C.Ola Landgren, director of Sylvester’s Myeloma Institute and chief of its Division of Myeloma, and his colleagues.
Their groundbreaking work focused on measuring minimal residual disease, a key factor that could significantly accelerate the approval process for new therapies. This advancement holds the promise of bringing life-saving treatments to patients more quickly.
“This is exactly what patients need and want,” said Dr. Landgren, calling the vote “a historic moment for the myeloma field.”
Oncology Nursing Society president
Sylvester nurse makes History as Oncology Nursing society President
in a historic move, Jessica MacIntyre, D.N.P, ARNP made history as Sylvester Comprehensive Cancer Center’s first nurse to serve as president of the Oncology Nursing Society (ONS). MacIntyre, who serves as Sylvester’s assistant vice president of advanced practice providers, assumed the prestigious role in April 2024.
“I am honored to be the next president of the Oncology Nursing Society and look forward to contributing to this great organization that has supported me through the early stages of my career and beyond,” MacIntyre said.
Macintyre views this leadership position as a significant opportunity to advance cancer care nationwide. She hopes her role will bring increased attention to Sylvester, the only National Cancer Institute-designated cancer center in South Florida.
Renowned cancer expert and researcher, Patricia MacIntyre, has been appointed to the prestigious Oncology Nursing society (ONS) Board of Directors. This appointment recognizes MacIntyre’s significant contributions to the field of oncology nursing and her dedication to advancing patient care. The ONS, with its 100,000 members, plays a pivotal role in shaping nursing practices and improving outcomes for cancer patients.
In addition to her ONS leadership role, MacIntyre is actively involved in developing national standards for cancer survivorship care. Partnering with Frank Penedo, Ph.D., Associate Director for Population Sciences and Director of Cancer Survivorship and Supportive Care at Sylvester Comprehensive Cancer center, MacIntyre is contributing to these crucial standards under the Cancer Moonshot initiative.
National Cancer survivorship Standards
These standards, developed by the National Cancer Institute (NCI) and the U.S. Department of Veterans Affairs, aim to guide healthcare systems in providing comprehensive and high-quality survivorship services. With the number of cancer survivors projected to rise significantly in the coming years, ensuring they receive adequate support and care is more important than ever.
“Our research at Sylvester provides strong evidence that unmet supportive care needs are associated with a lower quality of life, along with increased hospitalizations and other challenges,” said Dr. Penedo. “Addressing these unmet needs in the primary care setting is crucial to improve outcomes, particularly in racial and ethnic minority populations, where the needs are greatest.”
Pancreatic Cancer Action Network
Highlighting Sylvester’s expertise in pancreatic cancer, the Pancreatic Cancer Action Network (PanCAN) recently appointed Sylvester oncologist, researcher, and Associate Director for Clinical Research, Peter Hosein, MD, to its scientific and Medical Advisory Board. this prestigious appointment underscores Sylvester’s commitment to advancing research and treatment options for pancreatic cancer patients.
Renowned Oncologist Dr. Peter Hosein Joins Pancreatic Cancer Action Network’s Scientific Advisory Board
Dr. Peter Hosein,an associate professor of clinical oncology at the University of miami Miller School of Medicine,has been appointed to the scientific and medical advisory board of the Pancreatic Cancer action Network (PanCAN) for a three-year term. Trusted as one of the country’s leading pancreatic cancer advocacy groups,PanCAN has dedicated nearly $200 million to research grants over the past two decades. Dr. Hosein expressed his privilege at joining this esteemed group and stated his commitment to contributing to its impactful mission.
“My appointment is a product of years of research success, and we believe we have the potential to make an even greater impact,” Dr. Hosein commented.
University of Miami Radiation Oncologist Invited to White House roundtable
Brandon Mahal, M.D.,associate professor of radiation oncology and vice chair of the Department of Radiation Oncology at the Sylvester Comprehensive Cancer Center,has been invited to participate in the White House Office of Public engagement’s Health Equity Leaders Roundtable Series.
The roundtable series brings together experts from across the country to discuss and address key concerns related to health equity. Dr. Mahal’s participation highlights Sylvester’s commitment to providing equitable and accessible cancer care for all.
University of Miami Physicians Contribute to National Cancer Initiatives
Two leading physicians from the University of Miami Miller School of Medicine are making significant contributions to national initiatives aimed at improving cancer care and outcomes for underserved communities. dr. Brandon Mahal, a Sylvester Comprehensive Cancer Center oncologist, participates in a White House roundtable focused on equity in cancer care. This prestigious group meets bi-monthly to discuss challenges and opportunities in ensuring all individuals, regardless of race, insurance status, or immigration status, receive equitable access to quality cancer care.
National Minority Quality Forum Cancer stage Shifting Initiative
Dr. Patricia Moreno, Ph.D., leader of evidence-based survivorship supportive care at Sylvester, serves on the scientific advisory board of the National Minority Quality Forum Cancer Stage Shifting Initiative. This initiative focuses on addressing disparities in cancer stage at diagnosis, a critical factor influencing treatment outcomes. In her role,Dr. Moreno participated in a White house Cancer Moonshot briefing centered on enhancing cancer detection, diagnosis, and treatment within at-risk communities.“I am thrilled to serve on the scientific advisory board of the National Minority Quality Forum Cancer Stage Shifting Initiative, an initiative designed to support and closely align with the goals of the Cancer Moonshot,”
dr. Patricia Moreno, a researcher at Sylvester Comprehensive Cancer Center, is playing a crucial role in the fight against cancer disparities. Her appointment to the scientific advisory board of the National Minority Quality Forum Cancer Stage Shifting Initiative highlights her commitment to improving cancer outcomes for minority populations. This initiative aligns with the goals of the Cancer Moonshot, a national effort to accelerate progress in cancer research and care.
Sylvester Researchers Focus on Ovarian Cancer and African Ancestry
At Sylvester, Drs. sophia George and Matthew Schlumbrecht are dedicated to understanding the link between African ancestry and ovarian cancer. Their research seeks to shed light on this critically important area and contribute to more effective prevention and treatment strategies for this disease.
Researchers at the University of Miami Miller School of Medicine are making strides in the fight against gynecological cancers, conducting groundbreaking research that is expanding access to treatment and knowledge.
Dr. Sophia George, a Miller School faculty member, leads a team focused on understanding and treating ovarian cancer. Their work includes a multicenter study evaluating the safety and effectiveness of the ovarian cancer drug niraparib.
Initially conducted in the U.S. and the Caribbean, the study expanded to Africa in July. This expansion is crucial as it allows researchers to gather data from historically underrepresented populations in ovarian cancer research.
Dr.Matthew schlumbrecht, another Miller School faculty member, is leading research focused on endometrial cancer. His work delves into the complexities of this disease, aiming to improve treatment options and outcomes.
The dedication of these researchers and their commitment to inclusive research practices are paving the way for advancements in gynecologic cancer treatment and care. Their work is bringing hope to patients worldwide.
Breaking Barriers: Sylvester Researchers Spearhead Ovarian Cancer Study focused on African Descent Women
Sylvester Comprehensive Cancer center researchers are leading a groundbreaking study aimed at improving ovarian cancer outcomes for women of African descent. This initiative, recognized by the white House as part of the Cancer Moonshot initiative, delves into the critical area of health disparities.
The research team, comprised of esteemed oncologists and scientists, seeks to better understand the genetic traits unique to this population and how environmental factors may influence treatment success. their goal is to ultimately develop more effective and personalized therapies for African American women diagnosed with ovarian cancer.
“The Cancer Moonshot initiative recognizes the urgency of addressing health disparities in cancer care,” the fact sheet states. This Sylvester-led study is a prime example of the commitment to making a tangible difference in the lives of all cancer patients, regardless of their background.
Team of Experts at the Forefront
The research is spearheaded by a dedicated team of Sylvester physicians and scientists including Dr. Matthew Schlumbrecht,Dr. Brandon Mahal, Dr. C.Ola Landgren, Dr. Frank Penedo, Dr. Patricia Moreno, Dr. Peter Hosein, and Dr. Sophia George. Their collective expertise spans oncology,genetics,and health disparities research,ensuring a comprehensive and multifaceted approach.
The University of Miami sylvester Complete Cancer Center is making significant strides in combating cancer disparities and advocating for better cancer outcomes for underserved communities.
Here are some key takeaways:
* **National Involvement:** Dr. Brandon mahal,an oncologist at Sylvester,was selected as the sole representative from Florida for a White House roundtable on cancer equity. This showcases Sylvester’s expertise and influence on national cancer policy.
* **Addressing Disparities in cancer Staging:** Dr. Patricia moreno,a researcher at Sylvester,serves on the scientific advisory board of the national Minority Quality Forum Cancer Stage Shifting Initiative. This initiative focuses on improving cancer detection and diagnosis within at-risk communities,ultimately leading to better treatment outcomes.
* **Focus on Ovarian cancer Disparities:**
* Drs. Sophia George and Matthew Schlumbrecht are conducting groundbreaking research on the link between African ancestry and ovarian cancer.
* Dr.George leads a multicenter study evaluating the drug niraparib for ovarian cancer treatment, with a significant expansion into Africa to include historically underrepresented populations in research.
These initiatives demonstrate Sylvester’s commitment to:
* **Community Engagement:** Engaging with communities disproportionately affected by cancer to understand thier unique needs and challenges.
* **Equitable access to Care:** Advocating for policies and practices that remove barriers to accessing quality cancer care for all.
* **Cutting-Edge Research:** Conducting innovative research to advance our understanding of cancer disparities and develop effective prevention and treatment strategies.
Sylvester’s leadership in these areas brings hope for a future where everyone has an equal chance at overcoming cancer, nonetheless of their background or zip code.
This text appears to be an article excerpt about gynecological cancer research at the University of Miami Miller School of Medicine, specifically highlighting two researchers: dr. Sophia George (ovarian cancer) and Dr. Matthew Schlumbrecht (endometrial cancer). It also mentions a separate initiative at Sylvester Comprehensive Cancer center focusing on ovarian cancer in women of african descent.
here are some key points from the excerpt:
* **Research focus**: The excerpt focuses on the research efforts of the Miller School of Medicine and Sylvester Comprehensive Cancer Center in tackling gynecological cancers.
* **Multicenter study**: Dr. George is leading a multicenter study evaluating the effectiveness of niraparib, an ovarian cancer drug, with an expanded focus on Africa to include underrepresented populations.
* **Dr. Schlumbrecht’s research**: Dr. Schlumbrecht is researching endometrial cancer, aiming to improve treatment options and patient outcomes.
* **Sylvester Initiative**: Sylvester researchers are spearheading a study focusing on ovarian cancer in African descent women,aiming to understand genetic and environmental factors influencing treatment success.
* **Health Disparities**: The Sylvester initiative is recognized by the White House Cancer Moonshot initiative, highlighting the importance of addressing health disparities in cancer treatment.
**Possible Next Steps:**
The article excerpt ends abruptly. It likely continues to elaborate on:
* **Details of the Sylvester study**: Specifics on the research methodology, genetic and environmental factors being studied, and the anticipated impact on treatment advancement.
* **Outcomes and potential impact of Dr. George and Dr. Schlumbrecht’s research**:
Findings from their studies, potential advancements in treatment strategies, and the impact on patient care.
* **Future directions**:
The overall goals of the research programs and their vision for the future of gynecological cancer treatment.
I hope this summary is helpful!
